Adeno-Associated Virus as a Vector for Liver-Directed Gene Therapy

WEIDONG XIAO, SCOTT C. BERTA, MIN MIN LU, A. DAVID MOSCIONI, JOHN TAZELAAR, AND JAMES M. WILSON*

Institute for Human Gene Therapy and Departments of Molecular and Cellular Engineering and of Medicine, University of Pennsylvania, and the Wistar Institute, Philadelphia, Pennsylvania

Factors relevant to the successful application of adeno-associated virus (AAV) vectors for liver-directed gene therapy were evaluated. Vectors with different promoters driving expression of human α1-antitrypsin (α1AT) were injected into the portal circulation of immunodeficient mice. α1AT expression was stable but dependent on the promoter. Southern analysis of liver DNA revealed approximately 0.1 to 2.0 provirus copies/diploid genome in presumed head-to-tail concatamers. In situ hybridization and immunohistochemical analysis revealed expression in approximately 5% of hepatocytes clustered in the pericentral region. These results support the use of AAV as a vector for diseases treatable by targeting of hepatocytes.

The liver is an excellent target for in vivo gene therapy because hepatocytes are easily accessible to vectors injected into the circulation through large pores in liver capillaries (6). Nonviral gene delivery vehicles, based on liposomes and DNA-protein complexes, target hepatocytes in vivo, although gene transfer efficiency is low and expression is transient (20, 24). Recombinant adenoviruses target hepatocytes with higher efficiency but suffer from destructive cellular and blocking humoral immune responses (7, 11, 22).

Adeno-associated virus (AAV) has shown promise for in vivo gene therapy in a number of organs, such as skeletal muscle, central nervous system, and retina, where expression is efficient, stable, and associated with little inflammation or cellular immune response (1, 4, 5, 10, 12, 21). Results in the liver have been less consistent, with Snyder et al. providing the most impressive results by achieving sustained and therapeutic levels of factor IX in mice from an AAV vector utilizing a retroviral long terminal repeat (LTR) promoter (18).

The goal of this study was to further evaluate the potential of AAV as a vector for in vivo gene therapy of the liver. Studies were performed with human α1-antitrypsin (α1AT) as a reporter gene in murine models, because it allows quantitation of overall expression of the transgene through enzyme-linked imunosorbent assay (ELISA) of α1AT in serum. Vectors in which α1AT is driven from one of a number of promoters were constructed; they included (i) the 5′ flanking sequence and upstream enhancer sequences of the albumin gene (Alb), (ii) the 5′ flanking region of the immediate early gene of cytomegalovirus (CMV), (iii) the 5′ flanking region of the human phosphoglycerate kinase gene (PGK), (iv) the 5′ LTR of the Moloney murine leukemia virus, and (v) the chicken β-actin promoter fused to the enhancer region of the CMV immediate early gene (CB). Recombinant stocks of AAV for each vector were created by a transfection approach that does not require coinfection with adenovirus.

Hepatocytes were transduced in vivo following infusion of 10^11 genome equivalents of AAV into the portal circulation of immunodeficient mice. Figure 1 shows the level of human α1AT in serum of recipient mice for 18 weeks following gene transfer. The profile of expression with each vector was essentially the same, with the concentration of serum α1AT increasing during the first 6 weeks and thereafter stabilizing for the duration of the experiment. Total production of α1AT was consistent within each group but varied substantially between the different promoters. The highest expression was noted with the albumin and LTR constructs, with levels of α1AT ranging from 5 to 50 μg/ml. The CMV enhanced β-actin promoter (CB) yielded intermediate levels of α1AT (i.e., 1 to 10 μg/ml), whereas expression from the CMV and PGK promoters was substantially lower, at approximately 0.1 to 1 μg/ml. Additional experiments conducted with the albumin construct demonstrated a direct relationship between the dose of vector and transgene expression over a range of 3 × 10^3 to 1 × 10^11 vector genomes (data not shown).

The impact of the promoter on the level of transgene expression, noted in our study, may explain some discrepancies in the literature. Two groups failed to demonstrate significant expression of lacZ in the liver with AAV vectors containing the CMV promoter (3, 17). The performance of the murine leukemia virus LTR is more complex. The high level of activity of the LTR demonstrated in our study is consistent with the data of Snyder et al., who achieved substantial levels of factor IX with a similar vector (18), but is discordant with the results of Koeberl et al., where expression of alkaline phosphatase and factor IX from the LTR was low (13).

Additional studies were performed to evaluate the molecular state of the AAV genome in recipients. Livers were harvested from selected animals at 14 weeks after vector infusion and subjected to DNA hybridization analysis, the results of which are presented in Fig. 2. The total content of proviral DNA in liver was evaluated by digesting cellular DNA with enzymes that release an internal 800-bp fragment followed by DNA hybridization with human α1AT used as a probe (Fig. 2A). Proviral DNA was detected in livers from each animal, ranging from approximately 0.1 to 2 proviral copies per diploid genome. Undigested DNA produced a smear without a discrete band (Fig. 2B, lane 1). DNA restricted with endonucleases that contain a single site within the provirus yielded discrete bands whose apparent molecular weights were equivalent
FIG. 1. Levels of Human α-1AT in serum of mice after intraportal infusion of AAV vector. RAG-1 mice were injected with 10^{11} genomes of AAV vector, bearing different promoters, directly into the portal circulation via the spleen. Vector constructs contained the EcoRI fragment of pAT85 (from the American Type Culture Collection), spanning human α-1AT cDNA fused to the polyadenylation sequence from simian virus 40. Each panel presents serum α-1AT levels from multiple animals for vectors with different promoters measured up to 18 weeks after vector infusion. α-1AT was measured by an ELISA with α-1AT antibodies purchased from Sigma. The different promoters were as follows: CB, chicken β-actin promoter (−1 to +275) fused to enhancer sequences from the immediate early gene of CMV (23); CMV, promoter and enhancer of the immediate early gene of CMV spanning 795 bp of the 5′ flanking sequence; LTR, 2.3-kb Moloney murine leukemia virus LTR promoter isolated from pBR-MFG containing the LTR and intron (2); Alb, 2.4-kb murine albumin promoter from pAlbuPA2 (Ndel-to-KpnI fragment) containing 300 bp of the 5′ flanking sequence and the enhancer region from −8.5 to −10.4 kb (16); PGK, 0.5-kb PGK promoter from PGK-neo (from M. McBurney and K. Jardine). Experiments were repeated with a number of different vector preparations (CB [n = 1], CMV, [n = 3], LTR [n = 1], Alb [n = 5], and PGK [n = 2]), all with identical results. Recombinant AAV based on AAV serotype 2 was produced by simultaneously transfecting three plasmids into 293 cells and purifying vector from the cell lysate by sequential cesium chloride sedimentation. The three plasmids were vector, pWXS00 (inverted terminal repeats deleted from wild-type AAV and a 500-bp stuffer inserted between p5 and rep), and PFΔ13 (the adenovirus [Ad] helper construct created by deleting the RsrII fragment from pFG140 [Microbix, Toronto, Canada]). These preparations contained varying levels of replication-competent AAV (rcAAV), ranging from 1/10^3 to 1/10^5 (rcAAV genomes/vector AAV genomes), and no detectable Ad based on PFU assay (<1 Ad PFU/10^11 vector AAV genomes).

FIG. 2. Evaluation of the status of AAV vector genome in mouse liver by DNA hybridization analysis. RAG-1 mice were injected with 10^{11} vector genomes of AAV vectors containing different promoters. Livers were harvested at week 16 post-vector administration. DNA hybridization studies were performed with the whole cDNA of human α-1AT as a probe following the loading of 10 μg of restricted total cellular DNA per lane. (A) Lanes 1 to 4, control mouse genomic DNA spiked with 4, 0.4, 0.04, and 0 copies of human α-1AT plasmid digested with BamHI and EcoRV per diploid genome. This combination of enzymes releases an 800-bp fragment from the α-1AT cDNA. Lanes 5 to 9, genomic DNA from mice that received vectors with different promoters, as described in the legend to Fig. 1. DNA was digested with BamHI and EcoRV. The vector-specific fragment from DNA of transduced liver is 800 bp in length. The other two bands represent hybridization to endogenous mouse α-1AT sequence. (B) The liver genomic DNA from a mouse injected with vector expressing α-1AT from the Alb promoter was further analyzed. Lane 1, undigested genomic DNA; lane 2, genomic DNA digested with single-cut enzyme EcoRV; lane 3, genomic DNA digested with single-cut enzyme HindIII; lane 4, genomic DNA digested with both EcoRV and HindIII, which gives rise to a 3.1-kb internal fragment.
to that of the provirus (Fig. 2B, lanes 2 and 3). A smaller band of equal intensity was observed when total cellular DNA was restricted with two endonucleases that together release a 3.1-kb internal fragment (Fig. 2B, lane 4). These data are most consistent with a model in which AAV exists as an integrated head-to-tail concatamer similar to what is seen with latent AAV infection (14, 15, 19) and muscle transduced with AAV vectors (4, 21).

A number of histological analyses were performed to evaluate the frequency and distribution of AAV transduction fol-
Following intraportal infusion. Immunohistochemical hybridization analysis with an antibody to human α-1AT probe revealed staining over ~5% of hepatocytes throughout the liver (Fig. 3A to E) that was not found in mock-infected animals (data not shown). More transgene-expressing cells were clustered around central veins (Fig. 3B and C) than around portal triads (Fig. 3D and E). Similar frequency and distribution of transgene-expressing cells were found by in situ hybridization with a probe to human α-1AT (Fig. 3F to J). This does not agree with the findings of Snyder et al., who claimed expression of AAV-encoded tyrosine hydroxylase in cells around periportal regions (18). In our study, the pericentral localization of transduction was observed with each promoter, including the one used by Snyder et al., suggesting that other differences must play a role (e.g., method of delivery). The reasons for the observed gradient of transduction are unclear although not unexpected, considering that many genes demonstrate a gradient of expression along the portal to the central hepatic axis (9).

Data provided in this report and in the report of Snyder et al. (18) clearly support the use of AAV for targeting to hepatocytes genes that encode secreted proteins. What is the potential of AAV for treatment of metabolic diseases where the hepatocyte serves a catabolic or metabolic function, such as in familial hypercholesterolemia or urea cycle disorders? In situ
hybridization and immunohistochemistry revealed transduction in 5% of hepatocytes following infusion of 10^{11} vector genomes of recombinant AAV. Increased catalytic/metabolic capacity would best be achieved if transgene expression was distributed throughout a greater number of hepatocytes. Transgene expression appears to be proportional to dose up to 10^{11} vector genomes per injection, suggesting that increased doses will lead to more transduced hepatocytes. Direct confirmation of this hypothesis will require improved methods of AAV production to allow injection of higher vector doses.

In summary, AAV appears to be a viable alternative to adenoviruses and nonviral vectors for in vivo gene therapy to the liver. The advantages of immune evasion that attend their use in muscle (8) need to be confirmed in the liver, although preliminary results in immunocompetent mice suggest that elimination of AAV-transduced hepatocytes by cytotoxic T lymphocytes will not be as much of a problem as has been observed with adenoviruses (data not shown). A better understanding of the mechanism and distribution of proviral integration is needed.

We acknowledge the Vector and Cell Morphology Cores of the Institute for Human Gene Therapy and the technical support of Maria Houston-Leslie, Rosalind Barr, Melissa Casey, and Sarah Ehlen-Haecker.

This work was supported by grants from the NIH (P01 HD32649-04 and P30 DK47757-05 [to J. M. Wilson]) and by Genovo, Inc., a company J. M. Wilson founded and has equity in.

REFERENCES